NEUROCRINE BIOSCIENCES INC
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
NBIX$168.86+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in millions, except per share data) | September 30,2024 | December 31,2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $349.1 | $251.1 |
| Available-for-sale debt securities | 878.9 | 780.5 |
| Accounts receivable | 481.1 | 439.3 |
| Inventory | 45.8 | 38.3 |
| Other current assets | 121.7 | 97.8 |
| Total current assets | 1,876.6 | 1,607.0 |
| Deferred tax assets | 454.4 | 362.6 |
| Available-for-sale debt securities | 643.9 | 687.5 |
| Right-of-use assets | 257.3 | 276.5 |
| Equity investments | 126.7 | 161.9 |
| Property and equipment, net | 80.0 | 70.8 |
| Intangible assets, net | 34.5 | 35.5 |
| Other noncurrent assets | 61.6 | 49.6 |
| Total assets | $3,535.0 | $3,251.4 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $392.7 | $448.8 |
| Convertible senior notes | — | 170.1 |
| Other current liabilities | 37.0 | 35.9 |
| Total current liabilities | 429.7 | 654.8 |
| Noncurrent operating lease liabilities | 251.4 | 258.3 |
| Other noncurrent liabilities | 135.0 | 106.3 |
| Total liabilities | 816.1 | 1,019.4 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 220.0 shares authorized; 101.2 and 98.7 shares issued and outstanding, respectively | 0.1 | 0.1 |
| Additional paid-in capital | 2,623.2 | 2,382.0 |
| Accumulated other comprehensive income | 14.5 | 7.0 |
| Retained earnings (accumulated deficit) | 81.1 | (157.1) |
| Total stockholders’ equity | 2,718.9 | 2,232.0 |
| Total liabilities and stockholders’ equity | $3,535.0 | $3,251.4 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.